Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 4/20 | 0.36 |
| ▸ | MMP13 | P45452 | 4/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.36 |
| ▸ | BMP1 | P13497 | 4/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 4/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30415809 | 1.00 | MMP9 (0.36) | MMP9MMP13TRPM8BMP1MMP2 | |
| SCHEMBL30415869 | 0.89 | MMP9 (0.36) | MMP9MMP13BMP1MMP2MMP8 | |
| SCHEMBL21392070 | 0.89 | MMP9 (0.36) | MMP9MMP13BMP1MMP2MMP8 | |
| SCHEMBL21392149 | 0.87 | TRPM8 (0.38) | MMP9MMP13TRPM8BMP1TAS2R14 | |
| SCHEMBL30416019 | 0.87 | TRPM8 (0.38) | MMP9MMP13TRPM8BMP1TAS2R14 | |
| SCHEMBL29228052 | 0.85 | MMP9 (0.37) | MMP9MMP13BMP1MMP2MMP8 | |
| SCHEMBL21392147 | 0.84 | CXCR3 (0.35) | TRPM8TAS2R14CXCR3 | |
| SCHEMBL30416683 | 0.84 | CXCR3 (0.35) | TRPM8TAS2R14CXCR3 | |
| SCHEMBL21392335 | 0.82 | MLYCD (0.35) | MMP9MMP13BMP1MMP2MMP8 | |
| SCHEMBL29047788 | 0.82 | TRPM8 (0.37) | TRPM8TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | MMP9 849/4885MMP13 2184/4885TRPM8 2430/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | MMP9 849/4885MMP13 2184/4885TRPM8 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.